NE-ADME 2026 Agenda
*Speakers and titles are subject to change. Updated 05/13/2026
*TIME SLOTS LISTED BELOW ARE EDT!!!
|
Wednesday, June 10 2026 |
|||
| Talk Title |
Speaker |
Company |
Time EDT |
|
Registration & Breakfast |
7:30 - 8:30 |
||
|
Conference Opening |
Joseph Tillotson |
Pfizer |
8:30 - 8:40 |
|
Session I: AI, In-Silico Tools & Translational In Vitro Models |
|||
| Speaker Intro: Chris Rowbottom, Moderna & Jaydeep Yadav, Merck |
|
8:40-8:45 |
|
| From Chemical Structure to In Vivo Pharmacokinetic Profiles: Machine Learning‑Enabled Early Drug Discovery |
Nikhil Pillai |
Sanofi |
8:45 - 9:15 |
| Sponsor Talk - Hepatocyte Spheroids to Improve Duration of Drug Metabolism in in vitro Assays | Erik Willems |  |
9:15 - 9:25 |
| Speaker Intro: |
|
9:25 - 9:30 |
|
| Enabling Scalable and Reproducible QSP Modeling Using Certara IQ |
Joshua Apgar |
Certara |
9:30 - 10:00 |
| Break |
10:00 - 10:25 |
||
| Plenary Speaker Intro: Joseph Tillotson, Pfizer |
9:30 - 9:35 |
10:25 - 10:30 |
|
| Plenary Lecture: Case Studies on Metabolism-Guided Drug Design | Amit Kalgutkar | Pfizer |
10:30 - 11:10 |
|
Session II: In Vitro ADME & Modeling Approaches |
|||
| Speaker Intro: Vinayak Hosagrahara, C4 Therapeutics & Maria Fitzgerald, Ipsen |
11:10 - 11:15 |
||
| Overcoming the Translational Gap in Peptide Drug Development: Integrating MPS Systems with QSP Modeling |
Bjoern Olav Hald |
Novo Nordisk |
11:15 - 11:45 |
| Speaker Intro |
|
11:45 - 11:50 |
|
| Optimizing ADME/DMPK Strategy to Accelerate Drug Discovery |
Xiaohua Zhu |
Nimbus Therapeutics |
11:50 - 12:20 |
| Lunch |
12:20 - 1:30 |
||
| Speaker Intro: | Maria Fitzgerald | Ipsen |
1:30 - 1:35 |
| Sponsor Talk: Cryo-Fluorescence Tomography as a Next-Generation Imaging for DMPK and Translational Safety | Matt Silva |  |
1:35 - 2:00 |
|
Session III: NAM's, IVIVC Trends & Comparative MPS/Organ-on-Chip Platforms |
|||
| Speaker Intro: Steven Louie, BMS & Seema Kumar, Flagship Pioneering |
2:00 - 2:05 |
||
| Immunogenicity Risk Assessment: Enabling Quality by Design in Therapeutic Protein Discovery and Development | Christina Fu | Pfizer |
2:05 - 2:35 |
| Speaker Intro: Christopher Rowbottom, Moderna |
2:35 - 2:40 |
||
| Beyond Animals: Human‑Based NAMs Driving the Next Era of Biologics Translation | Alison Betts | Takeda |
2:40 - 3:10 |
| Break |
3:10 - 3:35 |
||
| Moderators: Seema Kumar, Flagship Pioneering & Steven Louie, BMS |
3:35 - 3:40 |
||
| Round Table Discussion: AI/ML in ADME, PK & Immunogenicity: What’s Actually Working? | Alison Betts, Xiaohua Zhu, Nikhil Pillai, Joshua Apgar, Amit Kalgutkar, Stefanus Steyn, Christina Fu, Vaibhav Maheshwari |
3:40 - 4:00 |
|
|
Session IV: Navigating ADME & Translational Hurdles in the Beyond Rule of 5 Chemical Space |
|||
| Speaker Intro: Paresh Chothe, AstraZeneca & Mitesh Patel, Novrtis |
4:00 - 4:05 |
||
| Quantitative Translational Pharmacology of PROTACs and Opportunities for Model-Informed Paradigms in R&D | Vaibhav Maheshwari | EMD Serono |
4:05 - 4:35 |
| Speaker Intro |
4:35 - 4:40 |
||
| Addressing Protac Plasma Protein Binding Challenges | Stefanus Steyn | Pfizer |
4:40 - 5:10 |
|
Closing Remarks |
Joseph Tillotson | Pfizer |
5:10 - 5:15 |
|
Reception |
5:15- 6:15 |
||